Celltrion Decides on Additional Share Buyback Worth 100 Billion KRW

To Be Conducted Through On-Market Purchases Starting June 27

Celltrion announced on June 26 that its board of directors had decided to carry out an additional share buyback worth approximately 100 billion KRW. The buyback will be conducted through on-market purchases starting June 27.

Celltrion has been continuously carrying out share buybacks and cancellations as part of its efforts to enhance shareholder value. Including this latest decision, the company has conducted share buybacks seven times this year, totaling around 650 billion KRW.

Celltrion stated that, amid internal and external uncertainties, it believes the company's intrinsic value is excessively undervalued. Therefore, it will continue to pursue various measures to increase market confidence and enhance shareholder value. Last month, as part of its shareholder return policy, the company conducted a free capital increase by allocating 0.04 new shares per common share, issuing a total of 8,494,384 new shares.

Celltrion is not only buying back shares but also maximizing shareholder value through share cancellations. On May 21, the company canceled treasury shares worth approximately 100 billion KRW. Through these actions, Celltrion is seeking to enhance shareholder value by reducing the number of shares in circulation, with a total of about 900 billion KRW in share cancellations planned for this year.

The company is also focusing on enhancing its corporate value. Last year, Celltrion achieved record annual sales of 3.5573 trillion KRW, the highest in its history, and plans to continue its growth trajectory to reach 5 trillion KRW in sales this year. In the first quarter of this year, Celltrion again posted record-high sales, demonstrating its growth momentum through the stable performance of new products and expansion into new markets.

Additionally, after establishing a portfolio of 11 biosimilars last year, Celltrion is accelerating the expansion of its pipeline this year, focusing on the development of next-generation antibody-drug conjugates (ADC) and multi-specific antibodies, further increasing its corporate value.

A Celltrion representative stated, "Through continuous share buybacks and cancellations, we are sending a clear message to the market about our strong commitment to enhancing shareholder value. At the same time, we are accelerating our efforts to become a 'global big pharma' through aggressive sales growth and investment in research and development (R&D). We will continue to do our utmost to strengthen our dominance in the global market and return profits to investors, enabling shared growth."